Immune modulating peptides for the treatment and suppression of multiple sclerosis.
Multiple sclerosis (MS) is a neurodegenerative disease in which the immune system recognizes proteins of the myelin sheath as antigenic, thus initiating an inflammatory reaction in the central nervous system. This leads to demyelination of the axons, breakdown of the blood-brain barrier, and lesion formation. Current therapies for the treatment of MS are generally non-specific and weaken the global immune system, thus making the individual susceptible to opportunistic infections. Antigenic peptides and their derivatives are becoming more prevalent for investigation as therapeutic agents for MS because they possess immune-specific characteristics. In addition, other peptides that target vital components of the inflammatory immune response have also been developed. Therefore, the objectives of this review are to (a) summarize the immunological basis for the development of MS, (b) discuss specific and non-specific peptides tested in EAE and in humans, and (c) briefly address some problems and potential solutions with these novel therapies.
Department of Pharmaceutical Chemistry, University of Kansas, Lawrence, KS 66047, USA.
Ahmed H
AH
Badawi
Teruna J
TJ
Siahaan
D000818:Animals; D004195:Disease Models, Animal; D006801:Humans; D007155:Immunologic Factors / Q000009:adverse effects / Q000627:therapeutic use*; D007167:Immunotherapy; D009103:Multiple Sclerosis / Q000276:immunology* / Q000628:therapy*; D010455:Peptides / Q000009:adverse effects / Q000627:therapeutic use*
D007155:Immunologic Factors; D010455:Peptides